TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: NEC of Bell stage 2 or more
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: 1-year AFS (Amputation-Free Survival)
Endpoint domain: Mortality/survival
Primary endpoint: Number of prompts required
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subsequent miscarriages
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Low birth weight newborns
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Sense of mastery and mental health
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: plasma F2‐isoprostane concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: MDA‐LDL autoantibody titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: plasma quercetin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: postoperative venous complications
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in past‐90‐day heavy drinking
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in baseline-adjusted mean Hb level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Serum levels of vitamin E and A
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TAP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mild anemia development
Endpoint domain: Adverse events/effects
Primary endpoint: short-term remission rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement rate of clinical syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RMQ score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: ED visits for suicide attempts or self-injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cranial spread of contrast
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Caudal spread of contrast
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Submucosal-dissection time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Coping planning
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Perceived opportunity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Aerobic exercise behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean decrease of mean IOP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: ECD decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: CCT decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: creatine kinase activity levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IGF-1Eb gene expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BMI change after 1 year of insulin therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: usual dietary behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nutritional outcomes
Primary endpoint: intentions to eat heart‐healthy foods
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Breathlessness benefit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Reduction in SMI scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: functional balance capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NDI success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total bicarbonate output
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Peak bicarbonate concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Clinical global impression improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: HAQ DI changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SF-36 physical functioning improvements
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: FACIT-Fatigue score improvements
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Freedom from gastrointestinal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Discontinuation of treatment due to unwillingness to continue
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Screw penetration rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Screw acceptable rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Sepsis
Endpoint domain: Mortality/survival
Primary endpoint: NEC Bell stage ≥ 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean end‐tidal concentration (FA = FA0)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Terminal half‐life (t1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time until a command was followed for the first time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-reported stress reduction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Attractiveness improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Decrease in DIBS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Th1/Th2 balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: HLA‐DR expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: need for opioids
Endpoint domain: Adverse events/effects
Primary endpoint: Need for intracervical prostaglandin treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Progression to Type 1 diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: isometric knee extension torque
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative incidence of lower respiratory tract infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: visual analogue scale scores on postoperative day 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean relative utilization change
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: serum retinol level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: serum anti-HBs levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: rate of weak or no-answer case
Endpoint domain: Adverse events/effects
Primary endpoint: intraoperative and postoperative morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postoperative wound hematoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: readability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: common carotid artery intima‐media thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: interadventitial diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: incidence of cardiovascular SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: incidence and frequency of emesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MACE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean gain of less pounds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: breathlessness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Complete and partial responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in knee OA-associated clinical symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acquisition of HIV during the first postpartum year
Endpoint domain: Mortality/survival
Primary endpoint: incidence of fallers
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in expressions of ICAM‐1, CD3, and HLA‐DR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Awareness of tactile and sound-based technology
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Use of Braille technology for reading and writing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of assistive technology for academic activities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Linguistic short-term memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of grade Ⅳ neutropenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of febrile neutropenia (FN)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: HBV specific CTL levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Non-specific CTL levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Negative conversion of HBV DNA and HBeAg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Shock skills station rating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preference for simulator as a teaching tool
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Frequency of episodes of incontinence (EI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Increase in IL-6 expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Increase in HLA-DR expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Magnitude of decrease in plasma VEGF levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak alanine aminotransferase (ALT) levels >10 times the upper limit of normal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Percentage of patients heartburn-free
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total treatment duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GI scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Timed Up‐and‐Go Test performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body sway in the anteroposterior and mediolateral directions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum TSH concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Geometric mean AUC(0-infinity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma sodium level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction of thyroid volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Iodine excretion in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Improvement in written comments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in voice symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of grade A pancreatic fistula
Endpoint domain: Adverse events/effects
Primary endpoint: Body Fat Percentage (%BF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discharge to a lesser level of care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Laboratory use reduction
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Delivered Kt/V(urea)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiovascular risk >/=10%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: treatment failure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Gingival status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Oral health outcomes
Primary endpoint: Inferior and middle turbinate volumes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy on TCM syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum IFN-gamma content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum IL-4 content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: HBV DNA rebound of more than 1 log from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: VAS (Visual Analog Scale) of neck pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Control of sphincter incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Improvement in ICIQ-SF score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Complete relief of overall primary symptoms of dyspepsia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: diagnostic agreement on malignancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: classification according to Bethesda
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sample quality rating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pa recurrence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of hospitalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24 hr mean BP decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Tinnitus troublesome level
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: reduced activation of neck extensor muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Recovery of intervertebral space and foraminal height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HBV DNA <300 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 5-year freedom from disease progression
Endpoint domain: Mortality/survival
Primary endpoint: Pacemaker rate response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: combined outcome of death and major disability
Endpoint domain: Mortality/survival
Primary endpoint: BMI z‐score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 6-min walk test improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage fall in FEV(1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: AUC (0‐60 min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Protective anti-HBs titers at 18 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: accumulative income
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: duration of welfare benefits
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: risk of a disability pension
Endpoint domain: Adverse events/effects
Primary endpoint: speed of performance on the 2-back WM task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Average graft peeling time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of radial tears
Endpoint domain: Adverse events/effects
Primary endpoint: Average difficulty grading
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Incident Rate Ratio (IRR) of PWIs for LBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Caloric content of meals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of patients referred
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: perceived control over falling
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Lacrimation scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hTERT mRNA expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first hospitalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: successful outcome rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of IgG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Levels of ESR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Ratio of IFN‐γ/IL‐4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Glycaemic control self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Glycaemic control behaviour
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: FMA balance score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: static balance index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dynamic balance index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arousals
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rapid eye movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quiet sleep (QS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postoperative triglyceride levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Vaccine-induced IgG levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: PDI (Psychomotor Development Index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: perceived stress scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Difference in mean scores between groups
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risk of radiographically defined vertebral fracture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: incidence of clinical (symptomatic) vertebral fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Frequency of PFXs practiced
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Proportion of patients requiring intraoperative ephedrine or any vasoconstrictor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in HbA(1c) from baseline to end point
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of patients achieving HbA(1c) target levels of ≤7.0%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of patients achieving HbA(1c) target levels of ≤6.5%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: decrease of calf muscle tightness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: decrease in pain complications
Endpoint domain: Adverse events/effects
Primary endpoint: rate of dmfs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean improvement in Boyarsky score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean improvement in AUA symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean maximum flow rate difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surgical complications rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: 30-day readmission rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of infants with rSBA titers ≥8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes